Advanced in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)

Dr. Andrew J. Hart

Hematology Oncology | Hematology | Oncology
Baptist Health Medical Group Inc
4003 Kresge Way, Suite 500, 
Louisville, KY 
Accepting New Patients
Advanced in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Baptist Health Medical Group Inc
4003 Kresge Way, Suite 500, 
Louisville, KY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Andrew Hart is a Hematologist Oncology specialist and a Hematologist in Louisville, Kentucky. Dr. Hart is rated as an Advanced provider by MediFind in the treatment of Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET). His top areas of expertise are Colorectal Cancer, Familial Colorectal Cancer, Thrombocytopenia, Lung Cancer, and Endoscopy. Dr. Hart is currently accepting new patients.

His clinical research consists of co-authoring 2 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in KY
Hospital Affiliations
Baptist Health Lagrange
Baptist Health Hardin
Baptist Health Louisville
Languages Spoken
English
Spanish
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Essence Healthcare
  • INSURANCE PLAN
  • MEDICARE MAPD
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

BAPTIST HEALTH MEDICAL GROUP INC
4003 Kresge Way, Suite 500, Louisville, KY 40207

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
Phase II Study of Bladder-SparIng ChemoradiatioN With Durvalumab in Clinical Stage III, Node PosItive BladdeR CancEr (INSPIRE)
Phase II Study of Bladder-SparIng ChemoradiatioN With Durvalumab in Clinical Stage III, Node PosItive BladdeR CancEr (INSPIRE)
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2025
Intervention Type: Procedure, Biological, Drug, Other, Radiation
Study Drugs: Carboplatin, Cisplatin, Doxorubicin, Durvalumab, Gemcitabine, Methotrexate, Vinblastine, Fluorouracil, Mitomycin C
Study Phase: Phase 2
Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer
Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2025
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Atezolizumab, Cisplatin, Fluorouracil, Gemcitabine, Mitomycin C
Study Phase: Phase 3
A Randomized Prospective Trial of Adjuvant Chemotherapy in Patients With Completely Resected Stage I or IIA Non-Squamous Non-Small Cell Lung Cancer Identified as Intermediate or High Risk by a 14-Gene Prognostic Assay
A Randomized Prospective Trial of Adjuvant Chemotherapy in Patients With Completely Resected Stage I or IIA Non-Squamous Non-Small Cell Lung Cancer Identified as Intermediate or High Risk by a 14-Gene Prognostic Assay
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2025
Intervention Type: Drug, Other
Study Drug: Adjuvant Chemotherapy
Study Phase: Not Applicable
View 3 Less Clinical Trials

2 Total Publications

A single nucleotide polymorphism in SLC7A5 is associated with gastrointestinal toxicity after high-dose melphalan and autologous stem cell transplantation for multiple myeloma.
A single nucleotide polymorphism in SLC7A5 is associated with gastrointestinal toxicity after high-dose melphalan and autologous stem cell transplantation for multiple myeloma.
Journal: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
Published: November 08, 2013
Similar Doctors
Distinguished in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Dr. John L. Huber
Hematology Oncology | Hematology | Oncology
Distinguished in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Dr. John L. Huber
Hematology Oncology | Hematology | Oncology

Baptist Health Medical Group Inc

4003 Kresge Way, Suite 500, 
Louisville, KY 
 (0.1 miles away)
502-897-1166
Languages Spoken:
English
See accepted insurances
Accepting New Patients

John Huber is a Hematologist Oncology specialist and a Hematologist in Louisville, Kentucky. Dr. Huber is rated as a Distinguished provider by MediFind in the treatment of Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET). His top areas of expertise are Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET), Chronic Lymphocytic Leukemia (CLL), Intraductal Papilloma, and Bone Marrow Aspiration. Dr. Huber is currently accepting new patients.

Distinguished in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Dr. Lowell B. Anthony
Oncology | Hematology Oncology
Distinguished in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Dr. Lowell B. Anthony
Oncology | Hematology Oncology

Kentucky Medical Services Foundation, Inc

2400 Greatstone Pt, 
Lexington, KY 
 (61.2 miles away)
859-323-7426
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Lowell Anthony is an Oncologist and a Hematologist Oncology provider in Lexington, Kentucky. Dr. Anthony is rated as an Elite provider by MediFind in the treatment of Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET). His top areas of expertise are Neuroendocrine Tumor, Carcinoid Syndrome, Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET), and Pancreatic Islet Cell Tumor.

Advanced in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Dr. Vivek R. Sharma
Hematology Oncology | Hematology | Oncology
Advanced in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Dr. Vivek R. Sharma
Hematology Oncology | Hematology | Oncology

University Of Louisville Physicians Inc

220 Abraham Flexner Way, 
Louisville, KY 
 (6.1 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Vivek Sharma is a Hematologist Oncology specialist and a Hematologist in Louisville, Kentucky. Dr. Sharma is rated as a Distinguished provider by MediFind in the treatment of Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET). His top areas of expertise are Familial Colorectal Cancer, Gastroesophageal Junction Cancer, Pancreatic Cancer, and Familial Pancreatic Cancer. Dr. Sharma is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hart's expertise for a condition
ConditionClose
    View All 55 Advanced Conditions
    View All 157 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile